Apigenin increases radiosensitivity of glioma stem cells by attenuating HIF-1α-mediated glycolysis
Ying Zhao1,2, Hui Huang1, Chang-Hao Jia1
1College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
Abstract:
Apigenin, a natural flavonoid compound present in a variety of edible plants and health foods, has an anti-tumor effect and inhibits hypoxia inducible factor-lα (HIF-1α) expression in hypertrophic cardiac tissues. However, whether or not apigenin has a radiosensitization effect on glioma stem cells (GSCs) is unknown. Our present study aimed to investigate the effect of apigenin and its possible mechanisms. The human GSCs SU3 and its radioresistance line SU3-5R were treated with apigenin, radiation, or their combination, and the cell proliferation, migration, colony formation, and intracellular lactic acid and glycolytic related protein expressions were determined. Additionally, a cell model with hypoxia-induced HIF-1α expression was used and treated with apigenin. The current results displayed that the combination of apigenin and radiation could synergically reduce the viability, colony formation, and migration of the both GSCs. Moreover, this combination could also decrease the radiation-induced increments of glycolytic production lactic acid in the both GSCs and related protein expressions, including HIF-1α, glucose transporter (GLUT)-1/3, nuclear factor kappa B (NF-κB) p65, and pyruvate kinase isozyme type M2 (PKM2). Further study confirmed that after treatment of hypoxia-cultured SU3 or SU3-5R cells with apigenin, the expression levels of HIF-1α, GLUT-1/3, NF-κB p65, and PKM2 proteins were reduced. These results demonstrated that apigenin could increase the radiosensitivity of GSCs and its radiosensitization mechanisms were attributable to the attenuation of glycolysis, which might result from the inhibition of HIF-1α expression and subsequent reductions of GLUT-1/3, NF-κB, and PKM2 expressions.
Insights
Apigenin enhances radiation therapy for glioma stem cells (GSCs) by reducing their viability and migration. This natural compound works by inhibiting glycolysis and key protein expressions involved in cell growth and survival.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Apigenin, a flavonoid, exhibits anti-tumor properties and inhibits hypoxia-inducible factor-1α (HIF-1α) in cardiac tissues.
- The radiosensitization potential of apigenin on glioma stem cells (GSCs) remains unexplored.
Purpose of the Study:
- To investigate the radiosensitization effect of apigenin on GSCs.
- To elucidate the underlying mechanisms of apigenin's radiosensitization, focusing on glycolysis and HIF-1α pathways.
Main Methods:
- Human GSCs (SU3) and their radioresistant counterparts (SU3-5R) were treated with apigenin, radiation, or a combination.
- Assays included cell viability, migration, colony formation, and measurement of intracellular lactic acid and related protein expressions.
- A hypoxia-induced HIF-1α cell model was utilized to assess apigenin's effects.
Main Results:
- Apigenin combined with radiation synergistically reduced GSC viability, colony formation, and migration.
- The combination therapy decreased radiation-induced lactic acid production and suppressed key proteins: HIF-1α, glucose transporter (GLUT)-1/3, nuclear factor kappa B (NF-κB) p65, and pyruvate kinase M2 (PKM2).
- Apigenin treatment alone reduced HIF-1α, GLUT-1/3, NF-κB p65, and PKM2 expression in hypoxia-cultured GSCs.
Conclusions:
- Apigenin enhances GSC radiosensitivity.
- Its mechanism involves attenuating glycolysis via inhibition of HIF-1α expression, leading to reduced levels of GLUT-1/3, NF-κB, and PKM2.
- Apigenin shows promise as an adjuvant therapy to improve glioma treatment outcomes.
More Related Videos
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
